Preclinical studies of PORCN inhibitors have demonstrated remarkable efficacy in colorectal cancer, especially those with high Wnt-ligand dependency, defined as those with RNF43 gene mutations and fusions in the RSPO gene family [144]; it remains to be seen how this translates to HCC as well as in clinical studies. The gene discussed is PORCN; the disease is hepatocellular carcinoma.